Premium
Human coxsackie adenovirus receptor (CAR) expression in transgenic mouse prostate tumors enhances adenoviral delivery of genes
Author(s) -
Bao Yunhua,
Peng Weidan,
Verbitsky Amy,
Chen Jiping,
Wu Lily,
Rauen Katherine A.,
Sawicki Janet A.
Publication year - 2005
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20265
Subject(s) - transgene , prostate cancer , cancer research , reporter gene , biology , genetic enhancement , genetically modified mouse , viral vector , prostate , gene , immunology , gene expression , cancer , recombinant dna , genetics
BACKGROUND Transgenic mice that recapitulate the progression of human diseases are potentially useful models for testing the effectiveness of new therapeutic strategies. Their use in pre‐clinical testing of adenovirally‐delivered gene therapies, however, is limited because of restricted cell surface expression of Coxsackie adenovirus receptor (CAR) in mice. METHODS To develop a more suitable transgenic mouse model for testing adenoviral‐based gene therapies for prostate cancer, we generated prostate specific antigen/human CAR (PSA/hCAR) transgenic mice in which a chimeric enhancer/promoter sequence of the human PSA gene drives expression of a functional hCAR coding sequence. Results Expression of an adenovirally‐delivered luciferase reporter gene in prostate tumor cells in bigenic mice (PSA/hCAR + TRAMP) was enhanced compared to the level in tumor cells lacking the PSA/hCAR transgene. CONCLUSIONS Breeding PSA/hCAR mice to existing transgenic mouse models for prostate cancer (e.g., TRAMP) results in improved mouse models for testing adenovirally‐delivered therapeutic genes. © 2005 Wiley‐Liss, Inc.